Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 11Osteosarcoma 5Rhabdomyosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Cardiotoxicity 3Sarcoma, Ewing 2Lymphoma, Large B-Cell, Diffuse 2Dendritic Cell Sarcoma, Interdigitating 2Blast Crisis 2Vomiting 1Sezary Syndrome 1Sarcoma, Synovial 1Sarcoma, Myeloid 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Neuroblastoma 1Nausea 1Myeloproliferative Disorders 1Mycosis Fungoides 1Malignant mesenchymal tumor 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Localized Extraskeletal Ewing Sarcoma 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1

Interventions

Doxorubicin 9Imatinib Mesylate 6pazopanib 4Ifosfamide 4Radiotherapy 3Gemcitabine 3Docetaxel 3pembrolizumab 2Radiation 2Neoadjuvant Therapy 2Mohs Surgery 2Biopsy 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2selinexor 1saracatinib 1sapanisertib 1ribociclib 1peposertib 1liposomal doxorubicin 1indolepropanol phosphate 1envafolimab 1cixutumumab 1brigimadlin 1avelumab 1X-Rays 1Watchful Waiting 1TTI-621 1Sunitinib 1Specimen Handling 1Razoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dermatofibrosarcoma × Dexrazoxane × Sarcoma × Clear all
NCT02584309 2023-11-07

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 2 Completed
73 enrolled 11 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡